Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRN | P28799 | 1/20 | 0.50 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | CPB2 | Q96IY4 | 15/20 | 0.47 |
| ▸ | MME | P08473 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | CPA1 | P15085 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | FNTA | P49354 | 1/20 | 0.44 |
| ▸ | FNTB | P49356 | 1/20 | 0.44 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29387045 | 0.90 | GRN (0.52) | GRNSORT1LTA4HCPB2MME | |
| SCHEMBL30799559 | 0.88 | CPB2 (0.48) | GRNSORT1LTA4HCPB2MME | |
| SCHEMBL30541625 | 0.88 | CPB2 (0.51) | GRNSORT1LTA4HCPB2MME | |
| SCHEMBL30732913 | 0.88 | CPB2 (0.51) | GRNSORT1LTA4HCPB2MME | |
| SCHEMBL9146938 | 0.86 | LTA4H (0.50) | GRNSORT1LTA4HCPB2MME | |
| SCHEMBL9146946 | 0.86 | LTA4H (0.50) | GRNSORT1LTA4HCPB2MME | |
| SCHEMBL30799798 | 0.85 | LTA4H (0.49) | GRNSORT1LTA4HCPB2MME | |
| SCHEMBL7751628 | 0.84 | CPB2 (0.51) | GRNSORT1LTA4HCPB2MME | |
| SCHEMBL30799634 | 0.82 | CPB2 (0.46) | GRNSORT1LTA4HCPB2MME | |
| SCHEMBL30070713 | 0.82 | CPB2 (0.52) | GRNSORT1LTA4HCPB2MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116985-A1 | STAPLED PEPTIDES AND METHODS THEREOF | PARABILIS MEDICINES, INC. | 2024-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116985-A1 | STAPLED PEPTIDES AND METHODS THEREOF | CTNNB1, APC, CTNNA1 | GRN 537/4885SORT1 1084/4885LTA4H 4132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.